白雲山(00874.HK):甲苯磺酸索拉非尼獲準上市銷售
格隆匯5月29日丨白雲山(00874.HK)發佈公告,近日,公司分公司廣州白雲山醫藥集團股份有限公司白雲山化學製藥廠(以下簡稱“白雲山化學製藥廠”)收到國家藥品監督管理局簽發的甲苯磺酸索拉非尼《化學原料藥上市申請批準通知書》。
白雲山化學製藥廠本次獲得甲苯磺酸索拉非尼《化學原料藥上市申請批準通知書》,表明該原料藥已符合國家相關藥品審評技術標準,可進行生產銷售,有助於豐富白雲山化學製藥廠抗腫瘤類產品的種類,提升本公司在抗腫瘤領域市場的競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.